



Docket No.: 237.00

BEFORE THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Application of: Scheiflinger et al.

Application No.: 09/661,992

Filing Date: 09/14/2000

For: FACTOR IX/FACTOR IXa ACTIVATING ANTIBODIES AND
ANTIBODY DERIVATIVES

) Group Art Unit: 1644
)
) Examiner: DeCloux, A.
)
)
)
)
)
)
)
)

Assistant Commissioner of Patents
U.S. Patent and Trademark Office
Box Sequence, P.O. Box 2327
Arlington, VA 22202

RESPONSE TO NOTICE TO COMPLY AND
PRELIMINARY AMENDMENT

Dear Sir:

In response to the Notice to Comply mailed July 1, 2002, please amend the above-identified application as follows:

IN THE CLAIMS:

Please amend Claim 7 as follows:

7. (Once Amended) An antibody derivative according to claim 6, wherein said CDR3 peptide comprises an amino acid sequence selected from the group consisting of:

Cys-X-X-Tyr-Gly-Asn-Ser-Pro-Lys-Gly-Phe-Ala-Tyr-X-X-Cys (SEQ ID NO: 105), wherein

X may be any desired amino acid;

Tyr-Gly-Asn-Ser-Pro-Lys-Gly-Phe-Ala-Tyr (SEQ ID NO: 5);

Asp-Gly-Gly-His-Gly-Tyr-Gly-Ser-Ser-Phe-Asp-Tyr (SEQ ID NO: 6); and

Phe-Arg-Asn-Arg-Gly-Met-Thr-Ala-Leu-Leu-Lys-Val-Ser-Ser-Cys-Asp (SEQ ID NO: 106).

REMARKS

The foregoing amendments to Claim 7 are being made for the purpose of adding sequence identification numbers to the above-identified application pursuant to 37 CFR § 821(d), as well as to respond to item number 7 in the Notice to Comply. In accordance with 37 CFR § 821(c), Applicants are submitting herewith a paper copy of the nucleotide and amino acid sequences disclosed in the above-identified application in the form of a Sequence Listing. The Applicants are also submitting this Sequence Listing in computer-readable form in accordance with 37 CFR § 821(e). The sequence listing information recorded in computer readable form is identical to the written paper sequence listing submitted herewith.